Answers are grounded in this paper and cite their sources.
The evolution of research in the field of antidepressant pharmacology registered a period of apparent stagnation after the appearance of multimodal agents (vilazodone, approved by FDA in 2011, and vortioxetine, approved in 2013) in the clinical use, which raised concern among mental health specialists, mainly due to the high rates of partial response or nonresponse in patients with major depressive disorder (MDD). Also, the reduced tolerability of some antidepressants, with an important incidence of adverse effects such as weight gain, sexual dysfunctions or sedation, supported the need for further pharmacological explorations in order to find new therapeutic solutions in MDD. The “new wave” of antidepressants includes agents with different mechanisms of action, namely partial agonism of type 1A serotoninergic receptors, glutamatergic modulation, simultaneous inhibition of the three monoamine transporters, allosteric modulation of GABA-A receptors, or the combination of distinct mechanisms of several pharmacological agents in a single tablet. Gepirone, esketamine, toludesvenlafaxine, zuranolone, brexanolone and the combination dextromethorphan+bupropion are the representatives of the new generation of antidepressants, all of which have been approved in the last five years by various national or regional agencies with responsibilities in the field of medicines authorization, for depressive disorders (MDD, postpartum depression, or treatment-resistant depression). These new agents came not only with the promise of better efficacy (esketamine, dextromethorphan+bupropion) or indications for which there were no specific treatments until now (brexanolone), but also of a superior tolerability profile (gepirone and toludesvenlafaxine). Given that the number of studies supporting the approval of these drugs is currently limited, pharmacovigilance activity and new independent studies will determine whether we can talk about a therapeutic paradigm shift in depression.
No takes yet. Share an insight, caveat, or question.
Petrescu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: